AI assistant
Xspray Pharma — Share Issue/Capital Change 2020
Sep 30, 2020
3129_rns_2020-09-30_f00bf9e2-14fa-4fec-aede-0ec753e7c0d8.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Number of shares and votes in Xspray
Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of the exercise of warrants under the company's incentive programs.
Through the exercise of warrants under the company's incentive program, the number of outstanding shares and votes has increased by 219,632 from 16,811,581 to 17,031,213, which corrects the number of shares presented in the press release August 21, 2020. The share capital has increased by SEK 219,632 from SEK 16,811,581 to SEK 17,031,213.
Referring to the press release on August 31, 2020 the shares now registered constitute the remaining part of the total number of warrants that have been exercised to subscribe for shares in accordance with the press release on August 21, 2020.
For further information, please contact:
Per Andersson, CEO, Xspray Pharma AB Phone: +46 (0) 706 88 23 48 E-mail: [email protected]
About Xspray Pharma
Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.
The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today's original drugs before the secondary patents expire. Xspray's goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 54 in December 2019. The company' s leading product candidates, HyNap-Dasa, HyNap-Sora and HyNap-Nilo, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Nexavar® (sorafenib) and Tasigna® (nilotinib), respectively. The launch of the first product candidate, HyNap-Dasa, is planned to take place in 2021. The substance patent for the original drug Sprycel® (dasatinib) expires at the end of 2020, and the secondary patents in 2026, which offers Xspray's HyNap-Dasa a period of five years of semi-exclusivity before other competitors gain access to the market.
The company has patented manufacturing technology, equipment and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm. www.xspraypharma.com
This information is information that Xspray Pharma AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2020- 09-30 14:00 CEST.